Waldenström macroglobulinemia

The abnormal B-cell population has features of both lymphocytes and plasma cells and usually involves the marrow. The IgM protein it makes can cause problems in addition to the cells themselves.

An IgM protein alone does not establish Waldenström macroglobulinemia. Marrow findings and other tests distinguish it from IgM MGUS and other disorders. MYD88 and CXCR4 mutation testing can help characterize the disease and inform treatment.

Acquired changes in B-cell growth and signaling contribute to the lymphoma. A MYD88 mutation is common but is not present in every case and is not a diagnosis by itself.

The disease mainly affects older adults. Some familial clustering is recognized, but the cause in an individual is usually unknown. It is not contagious.

Marrow involvement can cause anemia and fatigue. Enlarged lymph nodes or spleen, weight loss and night sweats may occur.

IgM can thicken the blood, causing hyperviscosity with headache, blurred vision or bleeding. It can also contribute to neuropathy, cold-related circulation problems or immune destruction of blood cells. Which effects are present matters more than treating an IgM number in isolation.

People without symptoms or organ problems may be monitored. When treatment is needed, options include anti-CD20-based combinations, BTK inhibitors and other selected systemic therapies. Prior treatment, mutation profile, comorbidities and patient preferences affect the choice.

Symptomatic hyperviscosity may need urgent plasma exchange to remove circulating IgM. This helps the immediate problem but does not eliminate the marrow clone, so disease-directed treatment is usually also required.

Autologous transplantation can be an option for selected fit patients with responsive relapsed disease, but is not standard first-line care. Allogeneic transplantation is much less common because treatment-related risks must be weighed against several effective non-transplant options.

Care may involve long periods of observation, ongoing oral treatment or scheduled drug cycles. Fatigue and neuropathy can affect daily life even when the lymphoma changes slowly.

The team can explain which new symptoms might indicate hyperviscosity or another complication and when to seek prompt help. Treatment monitoring may include blood counts, IgM, infection risk and regimen-specific effects.

Most people with Waldenström macroglobulinemia do not need a registry donor. Plasma exchange, ordinary transfusions and autologous stem cell rescue are different procedures from an allogeneic transplant.

A suitable donor is relevant only if allogeneic transplantation is selected in an uncommon clinical situation. Joining a registry supports patients who need donated cells across many diseases, rather than being the usual next step for this condition.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?